Clario, a leader in endpoint data solutions for clinical trials, has acquired NeuroRx, an imaging analysis expert in multiple sclerosis. This acquisition enhances Clario's neuroscience capabilities. NeuroRx's founder, Douglas Arnold, M.D., will join Clario as Senior Scientific Advisor. Clario also plans to acquire WCG’s eCOA business, further strengthening its neuroscience expertise.

Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neurosciencePHILADELPHIA, March 10, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases

PHILADELPHIA - October 10, 2024 - Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency.